Pluri Q3 2025 Earnings Report

Pluri EPS Results

• Actual EPS: -$0.94
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Pluri Revenue Results

• Actual Revenue: $0.43 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Pluri Announcement Details

• Quarter: Q3 2025
• Date: 5/13/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Pluri (NASDAQ:PLUR) (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies. Its PLX cell therapies have been evaluated in clinical studies targeting critical limb ischemia, hematopoietic support following radiation exposure and tissue repair in musculoskeletal injuries. The company has also received grant funding for programs addressing acute radiation syndrome and continues to explore additional indications in immune and inflammatory diseases.

Headquartered in Haifa, Israel, Pluri operates a GMP-certified manufacturing facility capable of supporting commercial-scale production. The company’s global footprint extends to clinical trial sites and partnership agreements in the United States, Europe and the Asia-Pacific region. Pluri’s leadership team brings extensive expertise in regenerative medicine, cellular manufacturing and regulatory affairs as it works toward potential market authorization and broad clinical adoption of its cell therapy products.